AEAhmed A. Abo Elnaga

Ahmed A. Abo Elnaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed A. Abo Elnaga has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Measurements and management of multiple sclerosis-related fatigue: an umbrella review and meta-analysis

    by Yousef Hawas, Ahmed Abdelmageed, Mohamed Abouzid, Abdallah Ashraf Hamad, Mohamed El-Moslemani, Habiba Tariq Saeed, Esraa Y. Salama, Mohammad Al Diab Al Azzawi, Dalia Kamal Ewis, Abdelfattah Arafa, et al.

    Multiple sclerosis (MS) is an autoimmune-mediated disorder of the central nervous system (CNS) where inflammation, demyelination, and neurodegeneration occur [1]. It is considered the most common n...

  • Open Access

    Treatment‐Line‐Specific Outcomes of Obinutuzumab in Membranous Nephropathy: A Systematic Review and Meta‐Analysis

    by Abdelrahman M. Elettreby, Ahmed A. Abo Elnaga, Faisal A. Al-Harbi, Sayed Sayem, Tamara Aburiash, Alam Eldin Musa Mustafa, Dina Khodeer, Ahmed Mohamed Aboelkheir, Mostafa Gamal

    Background: Primary membranous nephropathy (PMN) is an autoimmune glomerulonephritis triggered by B‐cell dysfunction, where rituximab achieved clinical remission in about 55%–65% of patients, while 35%–45% of patients are nonresponders. Obinutuzumab, a humanized type II anti‐CD20 monoclonal antibody that showed more profound B‐cell depletion, may improve treatment outcomes in both treatment‐naïve and refractory patients. This systematic review and meta‐analysis evaluate the clinical and immunological outcomes of obinutuzumab in PMN. Methods: We performed a systematic literature search across PubMed, Scopus, and Web of Science through January 2026 to identify studies assessing the effect of obinutuzumab in PMN. We performed meta‐analyses using the meta package in R software. Results: As first‐line therapy, pooled complete response was 0.324, rising from 0.257 at 6 months to 0.485 at 12 months, and partial response was 0.508. Clinical remission and immunological response were both high ranging between 81% and 89%. As second‐line therapy after rituximab, complete response was lower (18.1%) but partial response remained high (54.7%), with clinical remission increasing to 83.5% at 12 months and immunological response improving significantly to 90.5% at 12 months. In rituximab‐refractory patients, complete and partial response rates were 27.8% and 54.3%, respectively, with clinical remission improving notably by 12 months (84.5%). Secondary analyses showed increased serum albumin and reduced proteinuria over time. Conclusion: Obinutuzumab was associated with clinical and immunological remission in PMN. Clinical and immunological responses were observed across treatment‐naïve, previously treated, and rituximab‐refractory populations, though differences between these nonrandomized treatment‐line groups should not be interpreted as comparative efficacy. No clear short‐term change in kidney‐function measures was detected.

  • Analgesic effects of erector spinae plane block in patients undergoing nephrectomy: a systematic review and meta-analysis of randomized controlled trials

    by Ahmed A. Abo Elnaga, Abdelrahman M. Elettreby, Omnia Samy El-Sayed, Jaisingh Rajput, Mohamed Samir A. Zaki, Mohamed A. Alsaied

    Background Postoperative pain management remains a massive challenge after renal surgeries. The erector spinae plane block (ESPB) is a promising regional analgesia for pain management after nephrectomy. Unlike other regional anesthesia techniques, ESPB is relatively simple to perform and has been shown to provide effective pain relief in various surgical contexts. We aim to evaluate the analgesic effects of ESPB after nephrectomy, with the goal of providing evidence-based guidance for postoperative pain management in nephrectomy patients. Methods A comprehensive and meticulous literature search was conducted on PubMed, Scopus, Web of Science, and Cochrane Library till September 2024. Review Manager software was used to pool dichotomous and continuous data. We employed the risk of bias tool to evaluate the quality of the evidence, ensuring a thorough and robust analysis. Results This systematic review identified fourteen clinical trials of 897 patients that met the inclusion criteria. Meta-analysis results demonstrated that the ESPB significantly reduced pain scores at rest compared to no block at 30 min, 1 h, and 2 h postoperatively (p < 0.00001). In the intermediate recovery phase, ESPB also resulted in significantly lower pain scores at 4, 6, and 12 h (p < 0.001). At 24 h, ESPB continued to show a significant pain reduction compared to no block (SMD = -0.65, p < 0.0001). Less opioid consumption and prolonged time to first rescue analgesia were noticed in ESPB groups (MD = -29.56 mg, p < 0.00001), (SMD = 3.56 min, p = 0.001) respectively. ESPB showed a lower risk of postoperative nausea and vomiting. Conclusion This review demonstrated significant postoperative analgesic effects of ESPB with lower risks of postoperative nausea and vomiting in nephrectomy. However, the need for further studies to provide conclusive evidence is urgent and paramount in our field.